Dallas, TX -- (SBWIRE) -- 07/08/2015 -- The report "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/klebsiella-pneumoniae-infections-pipeline-review-h1-2015-market-report.html

It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. Companies discussed in this Klebsiella Pneumoniae Infections Pipeline Review H1 2015 report include Arsanis Biosciences GmbH, Cellceutix Corporation, Debiopharm International S.A., Melinta Therapeutics, Inc, Merck & Co., Inc., Northern Antibiotics Oy, Nosopharm SAS, Novan, Inc., Pfizer Inc., Phico Therapeutics Ltd., Sarepta Therapeutics, Inc., Shionogi & Co., Ltd., Soligenix, Inc., Sumitomo Dainippon Pharma Co., Ltd., Syntiron LLC, Tetraphase Pharmaceuticals Inc., Theraclone Sciences, Inc., Trana Discovery, Inc.

Drug Profiles discussed in this report includes Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections, Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections, BXN-112, CB-027, CB-618, CC-1807, CTIX-1278, Debio-1454, dusquetide, IBN-1, Klebsiella pneumoniae vaccine, Monoclonal Antibodies for Klebsiella Pneumoniae Infections, Monoclonal Antibody for Klebsiella Pneumoniae Infections, MVX-506, NAB-7061, NAB-739, NAB-741, NOSO-95300, NVN-1000, NVN-4428, PT-4, RX-05, RXP-792, RXP-873, S-649266, Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections, SM-295291, SM-369926, Small Molecule for Gram-Negative Nosocomial Infections, Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections, Small Molecules to Inhibit DHFR for Infectious Diseases, TP-076, TP-138, TP-600.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=394573 . (This is a premium report priced at US$2000 for a single user License.)

Table of Contents

List of Tables
Number of Products under Development for Klebsiella Pneumoniae Infections, H1 2015 11
Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Development by Companies, H1 2015 (Contd..2) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Klebsiella Pneumoniae Infections - Pipeline by Arsanis Biosciences GmbH, H1 2015 22
Klebsiella Pneumoniae Infections - Pipeline by Cellceutix Corporation, H1 2015 23
Klebsiella Pneumoniae Infections - Pipeline by Debiopharm International S.A., H1 2015 24
Klebsiella Pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015 25
Klebsiella Pneumoniae Infections - Pipeline by Merck & Co., Inc., H1 2015 26
Klebsiella Pneumoniae Infections - Pipeline by Northern Antibiotics Oy, H1 2015 27
Klebsiella Pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2015 28
Klebsiella Pneumoniae Infections - Pipeline by Novan, Inc., H1 2015 29
Klebsiella Pneumoniae Infections - Pipeline by Pfizer Inc., H1 2015 30
Klebsiella Pneumoniae Infections - Pipeline by Phico Therapeutics Ltd., H1 2015 31
Klebsiella Pneumoniae Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2015 32
Klebsiella Pneumoniae Infections - Pipeline by Shionogi & Co., Ltd., H1 2015 33
Klebsiella Pneumoniae Infections - Pipeline by Soligenix, Inc., H1 2015 34
Klebsiella Pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 35
Klebsiella Pneumoniae Infections - Pipeline by Syntiron LLC, H1 2015 36
Klebsiella Pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 37
Klebsiella Pneumoniae Infections - Pipeline by Theraclone Sciences, Inc., H1 2015 38
Klebsiella Pneumoniae Infections - Pipeline by Trana Discovery, Inc., H1 2015 39
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Stage and Target, H1 2015 42
Number of Products by Stage and Mechanism of Action, H1 2015 44
Number of Products by Stage and Route of Administration, H1 2015 46
Number of Products by Stage and Molecule Type, H1 2015 48
Klebsiella Pneumoniae Infections Therapeutics - Recent Pipeline Updates, H1 2015 87
Klebsiella Pneumoniae Infections - Dormant Projects, H1 2015 92
Klebsiella Pneumoniae Infections - Discontinued Products, H1 2015 93

List of Figures
Number of Products under Development for Klebsiella Pneumoniae Infections, H1 2015 11
Number of Products under Development for Klebsiella Pneumoniae Infections - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Products, H1 2015 17
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Top 10 Targets, H1 2015 41
Number of Products by Stage and Top 10 Targets, H1 2015 42
Number of Products by Top 10 Mechanism of Actions, H1 2015 43
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 44
Number of Products by Top 10 Routes of Administration, H1 2015 45
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 46
Number of Products by Top 10 Molecule Types, H1 2015 47
Number of Products by Stage and Top 10 Molecule Types, H1 2015 48

Explore more reports on Infectious Diseases Therapeutics industry at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.